HeartMate 3 LVAD

About HeartMate 3 LVAD

The HeartMate​ 3™​ Left Ventricular Assist Device (LVAD) is a mechanical circulatory support device designed for patients with advanced heart failure. With significantly improved outcomes and survival comparable to heart transplant at 2 years, our LVAD device technology is making a better future possible for many patients with advanced heart failure.*^1-3 The HeartMate​ 3 LVAD has advanced the field of LVAD therapy and is setting the standard with innovation and outstanding clinical outcomes.¹

The Full MagLev Flow Technology within the HeartMate 3 LVAD maintains gentle blood handling to minimize complications and hemocompatibility-related adverse events.

HeartMate 3 LVAD with Full MagLev Flow Technology Pump offers:

• Fully levitated, self-centering rotor, which does not require hydrodynamic or mechanical bearings
• Large, consistent blood flow pathways, which reduces shear stress⁴
• Intrinsic pulsatility, which reduces stasis and minimize thrombus^4,5
   

Reimbursement & Coding Highlights

Our coding and reimbursement documents provide information about coverage, coding and payment, economic insights and supporting documentation for Abbott LVAD and mechanical circulatory support products.

National Coverage Determination for Ventricular Assist Devices

On December 1, 2020, the Centers for Medicare and Medicaid Services (CMS) updated the final decision memo for National Coverage Determination (NCD 20.9.1) for Ventricular Assist Devices.

CMS removed the pre-implant designations (bridge-to-transplant and destination therapy) in favor of central clinical criteria for qualification of VADs for the purpose of coverage and payment effective for dates of services on and after December 1, 2020.

To access the final decision memo and the analysis in its entirety please go to cms.gov.
 

For the full resource list, visit Reimbursement & Coding for left ventricular assist devices.

*Based on published data from separate datasets, which may involve different patient populations and other variables. Not a head-to-head comparison. Data presented for informational purposes only.
**HeartMate 3 LVAD demonstrated superiority in event-free survival (primary endpoint) in the MOMENTUM 3 trial compared to HeartMate II™ LVAD.
^§For a continuous-flow LVAD in a randomized controlled trial.
 

References

1. Mehra M, Uriel N, Naka Y, et al. A Fully Magnetically Levitated Left Ventricular Assist Device-Final Report. N Engl J Med. 2019;380:1618-1627.
2. Khush KK, Cherikh WS, Chambers DC, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth Adult Heart Transplant Report-2018; Focus Theme: Multiorgan Transplantation. J Heart Lung Transplant. 2018;37:1155-1168.
3. Teuteberg JJ, Cleveland JC Jr, Cowger J, et al. The Society of Thoracic Surgeons Intermacs 2019 Annual Report: The Changing Landscape of Devices and Indications. Ann Thorac Surg. March 2020;109(3):649-660.
4. Bourque K, Cotter C, Dague C, et al. Design rationale and preclinical evaluation of the HeartMate 3 Left Ventricular Assist System for hemocompatibility. Am Soc Artificial Int Organs. 2016;62:375-383.
5. Bourque K, Dague C, Farrar D, et al. In vivo assessment of a rotary left ventricular assist device-induced artificial pulse in the proximal and distal aorta. Artificial Organs. 2006;30:638-642.
6. Mehra MR, Goldstein DJ, Cleveland JC, et al. Five-year outcomes in patients with fully magnetically levitated vs axial-flow left ventricular assist devices in the MOMENTUM 3 randomized trial. JAMA. 2022;328(12):1233-1242. doi:10.1001/jama.2022.16197.
7. Schmitto JD, Shaw S, Garbade J, et al. Long-Term Results in Real World Patients Treated with HeartMate 3 LVAD for Advanced Heart Failure: Data from the ELEVATE Registry. European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting; October 8, 2022; Milan, Italy.